1H-Pyrrole-3-Carboxylic Acid, 5-[(Z)-(5-Fluoro-1,2-Dihydro-2-Oxo-3H-Indol-3-Ylidene)Methyl]-2,4-Dimethyl-

Synthesis of sunitinib free base via carboxamide coupling represents the highest-volume industrial demand for this pyrrole-3-carboxylic acid intermediate. The (Z)-configured exocyclic olefin is susceptible to isomerisation at elevated temperature and under basic conditions, making the condensation step with 2‑(diethylamino)ethylamine the most critical unit operation for stereochemical fidelity. A validated kilo-lab procedure charges the carboxylic acid (1.0 eq) and 1‑hydroxybenzotriazole hydrate (1.3 eq) into anhydrous N,N-dimethylformamide (8–10 vol), cooled to 0–5°C internal temperature in a glass-lined reactor equipped with a retreat-curve impeller. 1‑Ethyl‑3‑(3‑dimethylaminopropyl)carbodiimide hydrochloride (1.25 eq) is added portionwise while maintaining the jacket temperature at −5°C. After 30 min pre‑activation the amine side chain (1.05 eq) is dosed over 90 min, keeping the reaction mass below 8°C. Process analytical technology (PAT) data from production campaigns show that transient temperature spikes beyond 12°C elevate the (E)-isomer impurity from 0.3% to 1.7% within a single batch. The coupling is aged at 20–25°C for 16–18 h, quenched into purified water (15 vol), and extracted with dichloromethane. The organic phase is washed with 5% w/w sodium bicarbonate to remove residual DMF and then with water until conductivity falls below 50 µS/cm. After solvent swap to 2‑propanol, the sunitinib free base is crystallised by controlled cooling from 70°C to −5°C at 0.3°C/min, isolated on a Nutsche filter‑dryer, and dried under vacuum at 40°C until loss on drying ≤ 0.5%. The material typically meets USP Sunitinib Malate RS limits after salt formation with l‑malic acid (1.0 eq in acetone/water) and is released against a specification of 99.5% purity and (Z)-isomer content ≥ 99.0%, tested by the Ph.Eur. 2.2.46 chromatographic method with a C18 column, 431 nm detection, and a system suitability requirement of resolution ≥ 2.5 between (Z)‑ and (E)‑sunitinib.

At what stage does stereochemical scrutiny become mandatory for GMP batch release of the antineoplastic API?

The (Z)‑configuration is a pharmacopoeial identity criterion, yet the α,β‑unsaturated ketone-like bridge undergoes photostationary Z→E interconversion when exposed to ambient light. Consequently, every lot of the carboxylic acid intermediate and the downstream sunitinib malate is subjected to a dedicated stereoisomer purity test. For reference standard preparation, the (E)‑isomer is intentionally generated by irradiating a 0.5 mg/mL methanolic solution of the (Z)‑acid with 365 nm UV‑A light (intensity 8 mW/cm²) in a borosilicate flask at 25°C for 45 min. This photostationary state yields an (E)/(Z) ratio of approximately 76:24, consistent with published photokinetic data for sunitinib chromophores. Subsequent preparative reversed‑phase chromatography on a C18 column with a 0.05 M sodium phosphate pH 4.6/acetonitrile mobile phase isolates the (E)‑isomer at > 98% purity. The (E)‑standard is co‑injected with the (Z)‑acid to prepare a system suitability solution containing 0.5% (E)‑isomer. Acceptance criteria per USP 〈621〉 require a signal-to-noise ratio ≥ 10 for the (E)‑peak, tailing factor ≤ 2.0, and a resolution between (Z) and (E) of not less than 2.5. An interlaboratory qualification study performed on 250 mm × 4.6 mm, 5 µm columns demonstrated that column oven temperature must be controlled at 35°C ± 0.5°C to keep the relative retention time drift below 1.5% across systems. The carboxylic acid and its solutions are stored in amber glass under argon at 2–8°C; exposure to fluorescent light for more than 3 h produces detectable (E)‑isomer above the 0.10% internal limit. Quality control laboratories therefore handle all samples under yellow light (λ > 530 nm) to preserve the (Z)‑integrity prior to injection.

Parallel medicinal chemistry programs that explore peri‑FGFR and VEGFR inhibition regularly employ the carboxylic acid as a common building block for carboxamide library production. The free carboxyl group is activated without chromatographic isolation of the acyl donor, enabling a generic work‑up that accommodates primary, secondary, and sterically hindered amines. A manual parallel format batches 12–48 reactions in septum‑sealed vials. Each vial receives the acid (1.0 eq), the amine (1.1 eq), and O‑(7‑azabenzotriazol‑1‑yl)‑N,N,N′,N′‑tetramethyluronium hexafluorophosphate (1.15 eq) in 0.25 M anhydrous DMSO. N,N‑Diisopropylethylamine (3.0 eq) is added at 0°C, and the mixture is agitated on an orbital shaker at 450 rpm for 16 h at 22°C. LC‑MS monitoring (ESI positive, m/z scan 200–800, C8 column) indicates > 90% conversion for aliphatic amines; sluggish coupling with weakly nucleophilic anilines is accelerated by pre‑heating the activation mixture to 40°C for 30 min prior to amine addition, though the (Z)‑retention drops by 2–4%. Quenching with 0.5 M ammonium chloride, extraction with ethyl acetate, and SCX‑2 solid‑phase extraction remove residual starting acid and HOBt‑derived by‑products. Final compound purity ≥ 95% by UV‑254 nm area is accepted for profiling against a kinase panel; compounds intended for in vivo pharmacology are purified by preparative RP‑HPLC and lyophilised to > 98% purity. The resulting amide sublibraries are screened under Eurofins KinaseProfiler™ protocols at 1 µM ATP, and selectivity scores against FLT3 and KIT are benchmarked against the parent sunitinib free base. The building block strategy consistently delivers an average target residence time shift of less than 0.4 log units versus the batch‑made parent, confirming its utility for hit‑to‑lead expansion.

Metabolite standard SU12662 (N-desethyl sunitinib) is synthesised from the same pyrrole‑3‑carboxylic acid by coupling with N‑ethylethane‑1,2‑diamine. To prevent over‑alkylation and amidation at both nitrogens, the primary amine of the unsymmetrical diamine is temporarily masked. In a representative process, N‑ethylethane‑1,2‑diamine is treated with di‑tert‑butyl dicarbonate (0.95 eq) in dichloromethane at 0–5°C to yield the mono‑N‑Boc‑protected derivative. After aqueous work‑up, the protected amine (1.0 eq) is coupled with the carboxylic acid (1.0 eq) using 2‑(1H‑benzotriazol‑1‑yl)‑1,1,3,3‑tetramethyluronium tetrafluoroborate (1.1 eq) and triethylamine (2.5 eq) in dry acetonitrile at 25°C. The reaction is complete within 6 h (monitored by TLC, silica gel 60 F₂₅₄, ethyl acetate/hexane 7:3). Acidic deprotection with 4 M HCl in dioxane (10 vol, 2 h, 25°C), followed by evaporation and trituration with diethyl ether, furnishes SU12662 as the hydrochloride salt. The crude product is dissolved in methanol, treated with 1 M sodium hydroxide to pH 9–10, extracted, and then re‑acidified with 1 M HCl to pH 2–3 to precipitate the zwitterionic free base, which is freeze‑dried from water/tert‑butanol. The resulting off‑yellow powder shows a purity of 99.2% by CAD‑enhanced RP‑UPLC and a (Z)‑stereochemistry retention of 98.8%. It serves as an authentic calibrant in GLP bioanalytical method development, where the LC‑MS/MS MRM transition m/z 371.1 → 283.2 (positive electrospray, declustering potential 45 V, collision energy 27 eV) is monitored against the deuterated internal standard. The certified reference material is stored at −20°C over silica gel; bench‑top stability studies confirm less than 2% degradation after 6 h in human plasma at 37°C, which is crucial for metabolite‑safety testing as per ICH M3(R2).

If continuous flow is adopted for the carboxamide coupling, which residence time window avoids Z→E scrambling?

Transferring the EDC‑mediated coupling to a continuous meso‑scale reactor narrows the thermal history of the (Z)‑olefin and suppresses the accumulation of 1,3‑dicyclohexylurea, often the yield‑limiting impurity in batch mode. Two feed solutions are prepared: Feed A contains the carboxylic acid (0.50 M) and HOBt hydrate (0.65 M) in DMF; feed B is 0.55 M amine and 0.65 M EDC·HCl in DMF. The streams are pre‑cooled to −5°C and synchronously pumped through a T‑junction into a 0.5 mm ID PTFE tubular reactor of 10 mL internal volume, jacketed with silicone oil at 5°C. A back‑pressure regulator set at 3 bar prevents DMF degassing. Residence‑time screening between 5 min and 25 min reveals a sharp stereochemical cliff edge: at 10 min residence the (E)‑isomer is 0.22% (same as batch at 0–5°C); extending to 20 min raises it to 0.65%; at 25 min the (E)‑content surges to 1.9%, attributable to base‑catalysed isomerisation promoted by unreacted amine accumulated over longer contact times. The optimal window of 8–12 min yields sunitinib free base with 93–95% conversion and less than 0.3% (E)‑stereoisomer. After continuous quenching in‑line with 0.5 M citric acid, the organic phase is membrane‑separated and fed directly to a continuous crystallisation module operating at −5°C with 2‑propanol as anti‑solvent, producing particles with a D₅₀ of 45 µm and a span of 0.9. This integrated flow process reduces overall processing time from 22 h to 4 h and delivers the free base with a consistent stereochemical purity that meets Ph.Eur. monograph 2710 requirements without column-condition-dependent variability.

Forced degradation marker: the carboxy‑acid as principal hydrolysis product in stability‑indicating RP‑HPLC

Under hydrolytic stress the secondary amide bond of sunitinib is cleaved, releasing the title carboxylic acid and 2‑(diethylamino)ethylamine. This conversion is exploited to create a stability‑indicating test that resolves the degradation marker from intact API, formulation excipients, and process‑related impurities. A 200 µg/mL stock of sunitinib malate is subjected to five forced‑degradation conditions in accordance with ICH Q1A(R2): thermal (80°C, 48 h, solid state), acidic (1 M HCl, 60°C, 6 h), alkaline (0.1 M NaOH, 25°C, 1 h and then neutralised), oxidative (3% v/v H₂O₂, 25°C, 24 h), and photolytic (1.2 × 10⁶ lux·h visible + 200 Wh/m² UV according to ICH Q1B). Chromatographic separation is achieved on a 150 mm × 4.6 mm, 3.5 µm C18 column, with a mobile phase of 25 mM sodium phosphate pH 4.6 and acetonitrile gradient (10%→90% over 40 min), detection at 431 nm. The resulting forced‑degradation peak distribution is summarised below.

The alkaline stress armcleav produces the largest proportion of the carboxylic acid marker, whereas oxidative and photolytic pathways preferentially generate the (E)‑isomer. In stability‑indicating method validation per ICH Q2(R1), the carboxylic acid standard is used to determine a limit of quantitation of 0.03% w.r.t. the drug peak, with linearity established between 0.03% and 5.0% (correlation coefficient ≥ 0.9990). Recovery at 0.10%, 1.0%, and 5.0% spiking levels across 48‑month aged placebo excipient blends falls within 97–103%. The chromatographic method is therefore integrated into shelf‑life specification limits of sunitinib malate 50‑mg capsules, with a reporting threshold of 0.05%. No further manufacturing‑scale data are available for the specific impurity profile of this pyrrole acid as an isolated degradation product beyond the described alkaline hydrolysis route, but its use as a primary reference marker is well documented in regulatory submission packages for generic sunitinib formulations.